OncoSec Medical Inc. has entered a clinical trial collaboration and supply agreement with Merck to evaluate the combination of OncoSec’s ImmuoPulse IL-12 with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in a phase II clinical trial, referred to as PISCES.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
